 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 January 1996 | Volume 124 Issue 1 Part 2 | Pages 90-96
Objective: To describe the relation between glycated hemoglobin and the incidence or progression, or both, of diabetic microvascular complications in persons with insulin-dependent (IDDM) and non–insulin-dependent diabetes mellitus (NIDDM).
Design: Population-based cohort study.
Setting: An 11-county area in southern Wisconsin.
Patients: All persons with IDDM diagnosed before age 30 and taking insulin (n = 996) and a probability sample (based on duration of disease) of persons diagnosed with diabetes at age 30 or older who were either taking insulin (n = 674) or not taking insulin (n = 696) and who participated in a baseline examination from 1980 to 1982. Survivors of the cohort were re-examined again in 1984 to 1986 and 1990 to 1992.
Measurements: The incidence and progression of diabetic retinopathy was determined by masked grading of stereoscopic color fundus photographs using the modified Early Treatment Diabetic Retinopathy Study severity scale. Gross proteinuria was determined using a dipstick. Ten-year incidence of renal dialysis or transplantation or loss of tactile sensation or of temperature sensitivity was based on self-reported history.
Results: The glycated hemoglobin level at baseline was strongly related to the incidence or progression, or both, of diabetic retinopathy, the incidence of gross proteinuria, and the incidence of loss of tactile sensation or temperature sensitivity in persons with either IDDM or NIDDM.
Conclusions: These prospective epidemiologic data suggest that glycemic control is similarly related to the incidence and progression of diabetic microvascular complications in both IDDM and NIDDM. However, further evidence from clinical trials in persons with NIDDM is necessary to assess the risks and benefits of such treatment in preventing these complications.
Author and Article Information
From the University of Wisconsin Medical School, Madison, Wisconsin.
MECHANISMS OF DIABETIC COMPLICATIONS: THE GLUCOSE HYPOTHESIS
Relation of Glycemic Control to Diabetic Microvascular Complications in Diabetes Mellitus
Note: This article is one of a series of articles comprising an Annals of Internal Medicine supplement entitled "Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus: The Fifth Regenstrief Conference." To view a complete list of the articles included in this supplement, please view its Table of Contents.
Acknowledgments: The authors thank their collaborators, Karen Cruickshanks, PhD; Matthew D. Davis, MD; and Polly Newcomb, PhD, who provided scientific advice; the 452 Wisconsin physicians and their staffs who participated in and supported this study; and Terry Spennetta and Earl Shrago, MD, who provided laboratory support (P30 AM AG 26659, Public Health Service, National Institutes of Health, Bethesda, Maryland).
Grant Support: By National Institutes of Health grant EYO-3083 (R Klein, BEK Klein) and, in part, by Research to Prevent Blindness (Dr. Klein, Senior Scientific Investigator Award).
Requests for Reprints: Ronald Klein, MD, MPH, Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 610 North Walnut Street, 460 WARF, Madison, WI 53705-2397.
Current Author Addresses: Drs. Klein. Klein, and Moss: Department of Ophthalmology and Visual Sciences. University of Wisconsin-Madison, 610 North Walnut Street, 460 WARF, Madison, WI 53705-2397.
This article has been cited by other articles:
|
|
 |
|
  L. Gong, W. H. L. Kao, F. L. Brancati, M. Batts-Turner, and T. L. Gary Association Between Parental History of Type 2 Diabetes and Glycemic Control in Urban African Americans Diabetes Care, September 1, 2008; 31(9): 1773 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. Gerrits, H. L. Lutgers, N. Kleefstra, R. Graaff, K. H. Groenier, A. J. Smit, R. O. Gans, and H. J. Bilo Skin Autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular complications Diabetes Care, March 1, 2008; 31(3): 517 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Selvin, S. Marinopoulos, G. Berkenblit, T. Rami, F. L. Brancati, N. R. Powe, and S. H. Golden Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus Ann Intern Med, September 21, 2004; 141(6): 421 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Y. Wong, J. Coresh, R. Klein, P. Muntner, D. J. Couper, A. R. Sharrett, B. E.K. Klein, G. Heiss, L. D. Hubbard, and B. B. Duncan Retinal Microvascular Abnormalities and Renal Dysfunction: The Atherosclerosis Risk in Communities Study J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2469 - 2476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vincze and A. Parthan The Value of Home Monitoring Kits in Diabetes, Hypertension, Asthma, and Oral Anticoagulation Therapy Journal of Pharmacy Practice, June 1, 2004; 17(3): 182 - 196. [Abstract] [PDF]
|
|
|
|
|
|
A. J.M. Boulton, R. A. Malik, J. C. Arezzo, and J. M. Sosenko Diabetic Somatic Neuropathies Diabetes Care, June 1, 2004; 27(6): 1458 - 1486. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Riddle, J. Rosenstock, and J. Gerich The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care, November 1, 2003; 26(11): 3080 - 3086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden The Epidemiology of Complications Diabetes Care, May 1, 2002; 25(5): 924 - 932. [Full Text] [PDF]
|
|
|
|
|
|
B. P. Tabaei, A. S. Al-Kassab, L. L. Ilag, C. M. Zawacki, and W. H. Herman Does Microalbuminuria Predict Diabetic Nephropathy? Diabetes Care, September 1, 2001; 24(9): 1560 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Raskin, M. Rendell, M. C. Riddle, J. F. Dole, M. I. Freed, and J. Rosenstock A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes Diabetes Care, July 1, 2001; 24(7): 1226 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sone, B. K. Deo, and A. K. Kumagai Enhancement of Glucose Transport by Vascular Endothelial Growth Factor in Retinal Endothelial Cells Invest. Ophthalmol. Vis. Sci., June 1, 2000; 41(7): 1876 - 1884. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. R. Williamson, A. E. Hunt, J. F. Pope, and N. M. Tolman Recommendations of Dietitians for Overcoming Barriers to Dietary Adherence in Individuals With Diabetes The Diabetes Educator, March 1, 2000; 26(2): 272 - 279. [Abstract] [PDF]
|
|
|
|
 |
|
 F. L. Ferris, M. D. Davis, and L. M. Aiello Treatment of Diabetic Retinopathy N. Engl. J. Med., August 26, 1999; 341(9): 667 - 678. [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. de Grauw, E. H van de Lisdonk, R. R. Behr, W. H. van Gerwen, H. J. van den Hoogen, and C. van Weel The impact of type 2 diabetes mellitus on daily functioning Fam. Pract., April 1, 1999; 16(2): 133 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Berlowitz, A. Ash, R. Friedman, E. Hickey, B. Kader, and M. A. Moskowitz Problems in Assessing Diabetes Control in an Ambulatory Setting American Journal of Medical Quality, June 1, 1998; 13(2): 89 - 93. [Abstract] [PDF]
|
|
Article
